Sorafenib Tosylate

CHEMBL1200485 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

637.0 g/mol

LogP

—

Phase

4

A tosylate salt form of sorafenib with the same therapeutic properties. This multi-targeted oral kinase inhibitor blocks several proteins that cancer cells use to grow new blood vessels and divide, effectively cutting off tumor blood supply and directly slowing cancer cell proliferation.

Moleküler Ağırlık

637,0000 g/mol

TPSA

155,00 Å²

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Hepatitis C Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1

InChI

InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)

Molecular Formula

C28H24ClF3N4O6S

HBD / HBA

4 / 10

Döndürülebilir Bağlar

6

Ağır Atomlar

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A tosylate salt form of sorafenib with the same therapeutic properties. This multi-targeted oral kinase inhibitor blocks several proteins that cancer cells use to grow new blood vessels and divide, effectively cutting off tumor blood supply and directly slowing cancer cell proliferation.

Yes, Sorafenib Tosylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200485. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 406563. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Sorafenib Tosylate PillFYI'da

Yapı

Hızlı Veriler

Formül: C28H24ClF3N4O6S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.